Skip to main content
Day.News — Local News. Real Community.
ASHFORD DAY NEWS
Local News. Real Community.

State News

08/21/2026 · Ashford

Full Edition
FDA Approves Subcutaneous Lecanemab for Early Alzheimer's Treatment

FDA Approves Subcutaneous Lecanemab for Early Alzheimer's Treatment

The Food and Drug Administration has approved LEQEMBI IQLIK (lecanemab-irmb), a subcutaneous injection for early Alzheimer's disease. This formulation allows for at-home dosing, broadening administration options for patients.

08/21/2026
Read Story
Politics

U.S. Implements New Visa Restrictions Targeting Cybercrime, Sextortion

The U.S. government announced a new visa restriction policy on July 23, 2026, targeting individuals linked to cybercrime, including online investment scams and sextortion. The policy extends to immediate family members of those implicated. Officials cite online investment scams defrauding U.S. citizens of at least $10 billion in 2024.

08/21/2026

Health

Survey Identifies Generational Differences in Healthcare System Perceptions

A recent national survey reveals differences in how age groups perceive the U.S. healthcare system. Gen Z and Millennial voters more frequently identified systemic failures, especially regarding women's health services.

08/21/2026

Education

Middle School Reading Scores Decline for Lowest-Performing Students, NWEA Study Finds

A new study by NWEA, a K-12 assessment organization, reports a persistent decline in reading scores for the lowest-performing middle school students. The research identifies this trend as ongoing since 2020. The study also highlights state policies showing potential in addressing these educational outcomes.

08/21/2026

Business

Egan-Jones Report Details AI's Influence on Industries and Investment Risk

Egan-Jones released an analysis detailing how artificial intelligence and autonomous technologies reshape industries. The report outlines challenges to existing business models and new considerations for institutional investors and risk management.

08/21/2026

Health

FDA Approves Subcutaneous Leqembi Starting Dose for Alzheimer's Treatment

The FDA has approved a weekly subcutaneous starting dose for Leqembi, a drug for early Alzheimer's. This approval provides an alternative administration method for patients. The Alzheimer's Drug Discovery Foundation commented on the development.

08/19/2026

More State News

Sponsored

Advertisement

Local Venues

View all

Advertisement

Advertisement

Upcoming Events

View all

SEP

03

Charley Crockett- Age of the Ram Tour

7:30 PM

SEP

19

Florida St. at Alabama

19:30

SEP

19

Miles at Clark Atlanta

22:00

Announcements

View all
!

Public Hearing Announced for New Regulations by AG's Office

NOTICE IS HEREBY GIVEN that the Alabama Attorney General's office will hold a public hearing concerning proposed regulations pertaining to [specific area of regulation, if mentioned in original content]. The hearing is scheduled for [Date] at [Time] in the [Location/Room Number] at the Attorney General's office, [Address]. Written comments will also be accepted until [Date]. Further details and the full text of the proposed regulations are available on our website.

!

Alabama AG Website Sitemap Available

This is the sitemap for the Alabama Attorney General's website. It contains links to various pages and resources for users to access information. The sitemap is organized into multiple parts for better navigation.

!

Unknown City Council to Hold Public Hearing on Zoning Amendments Next Tuesday

NOTICE IS HEREBY GIVEN that the City Council of Unknown will conduct a public hearing on the following matter: Proposed amendments to the Unknown Zoning Ordinance, Section 4.1, regarding commercial property setbacks. The hearing will take place on Tuesday, October 27, 2023, at 7:00 PM in the City Council Chambers, located at 123 Main Street, Unknown, AL 35XXX. All interested parties are invited to attend and present their views. Written comments may be submitted to the City Clerk prior to the hearing.

Advertisement

Advertisement

Advertisement

Advertisement